Integre Asset Management LLC Sells 24,934 Shares of Hologic, Inc. (HOLX)
Integre Asset Management LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 81.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,707 shares of the company’s stock after selling 24,934 shares during the period. Integre Asset Management LLC’s holdings in Hologic were worth $229,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Hologic by 12.9% in the third quarter. Price T Rowe Associates Inc. MD now owns 41,308,679 shares of the company’s stock valued at $1,604,016,000 after buying an additional 4,729,190 shares during the last quarter. State Street Corp increased its position in Hologic by 9.8% in the fourth quarter. State Street Corp now owns 12,521,146 shares of the company’s stock valued at $502,336,000 after buying an additional 1,117,759 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Hologic by 5.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 7,623,050 shares of the company’s stock valued at $296,003,000 after buying an additional 427,112 shares in the last quarter. Northern Trust Corp increased its position in Hologic by 9.4% in the third quarter. Northern Trust Corp now owns 3,117,938 shares of the company’s stock valued at $121,070,000 after buying an additional 268,151 shares in the last quarter. Finally, BlackRock Group LTD increased its position in Hologic by 1.2% in the third quarter. BlackRock Group LTD now owns 2,590,845 shares of the company’s stock valued at $100,601,000 after buying an additional 31,930 shares in the last quarter. Institutional investors and hedge funds own 94.09% of the company’s stock.
Hologic, Inc. (NASDAQ:HOLX) traded up 0.33% during midday trading on Thursday, reaching $39.53. The company’s stock had a trading volume of 2,962,238 shares. The firm has a market capitalization of $11.04 billion, a price-to-earnings ratio of 33.79 and a beta of 1.10. Hologic, Inc. has a 12 month low of $32.64 and a 12 month high of $41.24. The stock’s 50-day moving average price is $39.90 and its 200-day moving average price is $38.83.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 1st. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.01. The business earned $734.40 million during the quarter, compared to analyst estimates of $725.01 million. Hologic had a return on equity of 27.17% and a net margin of 11.57%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company posted $0.46 EPS. Analysts predict that Hologic, Inc. will post $1.92 EPS for the current year.
This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of United States and international copyright legislation. The legal version of this report can be accessed at http://www.watchlistnews.com/integre-asset-management-llc-sells-24934-shares-of-hologic-inc-holx/1121063.html.
A number of research firms have recently weighed in on HOLX. Barclays PLC set a $45.00 price target on Hologic and gave the stock a “buy” rating in a report on Saturday, November 19th. Evercore ISI cut Hologic from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Wednesday, January 4th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Friday, December 16th. Bank of America Corporation lowered Hologic from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, Piper Jaffray Companies raised Hologic from a “neutral” rating to an “overweight” rating and increased their price target for the company from $44.00 to $48.00 in a research report on Wednesday, January 4th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Hologic currently has a consensus rating of “Buy” and an average price target of $44.47.
In related news, Director Elaine Ullian sold 9,423 shares of the stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $39.54, for a total transaction of $372,585.42. Following the completion of the sale, the director now directly owns 36,798 shares in the company, valued at $1,454,992.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 3,023 shares of the stock in a transaction on Monday, November 21st. The stock was sold at an average price of $38.32, for a total value of $115,841.36. Following the sale, the vice president now owns 13,260 shares of the company’s stock, valued at $508,123.20. The disclosure for this sale can be found here. 0.79% of the stock is owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.